Overbeek F, Pauwels E K, Broerse J J
Department of Diagnostic Radiology and Nuclear Medicine, University Hospital Leiden, The Netherlands.
Eur J Nucl Med. 1994 Sep;21(9):997-1012. doi: 10.1007/BF00238128.
During the last decade new data have become available on the mechanism of carcinogenesis and on cancer induction by ionizing radiation. This review concentrates on these two items in relation to the use of radiopharmaceuticals in diagnostic nuclear medicine. On the basis of reports of expert committees, the concept of radiation risk is elucidated for high and low doses. Mortality risk factors due to ionizing radiation are put in perspective to other risks. The extra risk for patients who undergo a scintigraphic examination for fatal cancer is very small and is of the order of 1.4 x 10(-4). It is most unlikely that this figure can even be verified by actual measurement since the majority of nuclear medicine patients will die of other causes before the radiogenic cancer manifests itself.
在过去十年间,关于致癌机制以及电离辐射诱发癌症方面出现了新的数据。本综述聚焦于与放射性药物在诊断核医学中的应用相关的这两个方面。基于专家委员会的报告,阐明了高剂量和低剂量辐射风险的概念。将电离辐射导致的死亡风险因素与其他风险进行了对比。接受闪烁扫描检查后患致命癌症的额外风险非常小,约为1.4×10⁻⁴。由于大多数核医学患者会在放射性癌症显现之前死于其他原因,这个数字甚至极不可能通过实际测量得到验证。